Lviv clinical bulletin 2016, 2(14)-3(15): 63-70

https://doi.org/10.25040/lkv2016.023.063

Assessment of Quality of Life in Patients with Chronic Systolic Heart Failure, Impact of Diuretics on Quality of Life

Posted onAuthorAdminЗалишити коментар / Leave a comment

V. Ivanov, Yu. Savitska, A. Kovalchuk

National Pirogov Memorial Medical University, Vinnytsya

Introduction. Quality of life (QoL) of patients with chronic heart failure (CHF) is an integral part of a comprehensive analysis of their condition and helps to evaluate the effectiveness of various methods of treatment and rehabilitation.

Using different medicines, including diuretics, has a significant impact on this indicator. According to the researches BADAPIC and EPISERVE, 86.0 % of people with CHF are treated with diuretic drugs constantly. The purpose of our study was to ascertain the impact of these drugs on QоL in patients with CHF.

Aim. To analyse the current literature information in order to assess the quality of life in patients with systolic chronic heart failure and the effect of diuretic therapy on this indicator.

Materials and methods. Retrospective analysis of 50 contemporary literary resources on the topic.

Results. Determining the level of QоL based on the analysis of indicators of patient self- assessment of restrictions that caused the disease. The main tool for this is the questionnaires.

Past studies have found a correlation between the results of a survey among patients with CHF and a number of clinical and demographic indicators. Because QоL indicators can be used for stratification of patients with heart failure risk for unfavourable prognosis.

Little is known about how to evaluate the effect of different drugs on QоL in patients with CHF. Diuretics are no exception to this rule.

Most studies on the impact of diuretic treatment on QoL in patients with CHF demonstrate superiority of loop diuretics torasemide compared to furosemide. This is caused by its pharmacokinetic and pharmacodynamic characteristics, providing it a higher safety profile, metabolic neutrality, faster and more substantial clinical improvement in patients with decompensated state, respectively, lower incidence and duration of hospitalization. In addition, torasemide treatment is more cost-effective compared to furosemide.

Torasemide slow release (SR) in the study showed comparable torasemide immediate release (IR) safety profile and diuretic effect. However, it caused significantly fewer emergency and urination in the first 6 hours after taking a diuretic, causing fewer domestic constraints and better perceived subjectively by patients. Obtained facts give a reason to believe that torasemide SR is more «comfortable» diuretic during prolonged maintenance treatment that can save a maximum degree of social activity and minimize its negative impact on QoL of patients with CHF.

Conclusions. Assessment of quality of life is an integral part of a comprehensive analysis of the patient, forecasting of possible adverse events, stratification of patients at risk adverse effects and determine the effectiveness of different diagnostic, therapeutic and preventive measures.

During an extended maintenance of diuretic in patients with systolic chronic heart failure a better effect on the quality of life indicators has a loop diuretics torasemide, especially a torasemide with slow release.

References

  1. Acuna C. Prolonged form of furosemide: what’s new? Heart Failure. 2014;3:31-40. (Russian).
  2. Belovol A. Clinical efficacy of furosemide in chronic heart failure. Zdorov’ja Ukrajiny. 2011;1:43-44. (Russian).
  3. Arutyunov AG, Dragunov DO, Arutyunov GP, Rylova AK, Sokolova AV. Effect of dosage forms a loop diuretic with a different release rate of the early and delayed the prognosis of patients with circulatory decompensation. Kardiologiya. 2014;9:24-32. (Russian).
  4. Bortsova M, Sitnikova M, Dorofeykov V, Fedotov P. Correction of circadian blood pressure profile in patients with severe heart failure: study FUTOR (furosemide / torsemide). Arterial hypertension. 2009;2:126-131. (Russian).
  5. Voronkov LG, Paraschenyuk LP. Quality of life in chronic heart failure: current aspects. Part I. Heart Failure. 2010;2:12-16. (Russian).
  6. Voronkov LG, Paraschenyuk LP, Lutsak EA. Quality of life in chronic heart failure: current aspects. Part II. Heart Failure. 2010;3:18-25. (Russian).
  7. Voronkov L, Bagriy A. Modern understanding of diuretic therapy in patients with CHF. Zdorov’ja Ukrajiny. 2013;3:25-26. (Russian).
  8. Geltser BI, Frisman MV. Modern approaches for evaluation of quality of life of patients kardyolohycheskyh. ClinicalMedicine. 2002;9:449. (Russian).
  9. Vatutin NT, Kalinkina NV, Каrtamysheva YeV, Khristichenko MA, Yeshchenko YeV. Depressive disorders and chronic heart failure. Ukrainian Cardiology Journal. 2013;3:117-124. (Russian).
  10. Zagravskaya IA. Comparative evaluation of the efficacy of diuretics and their impact on quality of life and prognosis in patients with chronic heart failure [dissertation]. Ryazan, 2010. 141 p. (Russian).
  11. Irkin O. The use of loop diuretics: furosemide whether the drug can be the first line? Zdorov’ja Ukrajiny. 2013;5:61. (Russian).
  12. Ivanov V. Influence of different modes of diuretic therapy on exercise tolerance, structural and functional heart status and quality of life in patients with chronic systolic heart failure. Ukrainian Cardiology Journal. 2013;1:96-104. (Ukrainian).
  13. Karpov Yu. Torasemide: recommendations for clinical use in patients with chronic heart failure and hypertension. Russian Medical Journal. Cardiology. Endocrinology. 2014;23:1676-1681. (Russian).
  14. Ryndinа NG, Kravchun PG, Shelest OM, Titova АYu, Mishina MM. The quality of life in anemic patients with chronic heart failure, depending on the presence or absence of chronic kidney disease. Zaporozhye medical journal. 2013;3(78):60-62. (Russian).
  15. Kobalava Zh, Kiyakbaev G. Ways of optimization of diuretic therapy in congestive chronic heart failure – a place of torasemide prolonged release. Kardiologiya. 2014;4:69-77. (Russian).
  16. Kryvenko V, Ghrinenko T, Kachan I. Quality of life as an objective criterion for effective diagnosis and treatment in modern medicine. Zaporozhye Medical Journal. 2011;6:91-96. (Ukrainian).
  17. Mazhak I. Categorical-conceptual frame-work of the study of quality of life related to the health of the economically active population of Ukraine [Internet]. 2013. Derzhavne upravlinnja: udoskonalennja ta rozvytok. 2013;12. Available from: http://www.nayka.com.ua).
  18. Mareev V, Vygodin V, Belenkov Yu. Diuretic therapy is effective oral doses of diuretics torasemide (Diuver®) and furosemide in treating patients with acute exacerbation of chronic heart failure (CHF-DUEL). Russian Heart Failure Journal. 2011;12(1):3-10. (Russian).
  19. Matveeva SV. The level of quality of life in patients with chronic heart failure in the outpatient phase of observation [dissertation]. Saratov, 2004. 130 p. (Russian).
  20. Zhirov I, Goryunova T, Osmolovskaya Yu, Tereshchenko S. Position slow release torasemide in treating CHF. Russian Medical Journal. Poly Clinic. Man and medicine. 2014;6:436- (Russian).
  21. Gendlin G, Samsonova Ye, Bukhalo O et. al. Methods of study of quality of life in patients with chronic heart failure. Russian Heart Failure Journal. 2000;4:11-12. (Russian).
  22. Novik A, Ionova T. Guide to the study of quality of life in medicine. Petersburg: Neva; Moskow: Olma-Press Zvezdnyy mir, 2002. 320 p. (Russian).
  23. Voronkov LG, Bagry AE, Koval OA, Tashchuk VK, Tseluiko VY. Rationale, protocol and results of Ukrainian multicenter study COMFORT-CH (Cooperative test conventional and modified release forms of torasemide in chronic heart failure). Heart Failure. 2014;2:17-22. (Ukrainian).
  24. Prykhodjko V. Torasemide, new and previously known key aspects of proper application in the treatment of chronic heart failure. News of Medicine and Pharmacy. 2015;2:3-4. (Ukrainian).
  25. Rudyk Yu, Bolotskikh A. Torasemide sustained release – with modern antialdosterone diuretic action in treating patients with heart failure. Zdorov’ja Ukrajiny. 2013;1:31-32. (Russian).
  26. Tebloev K, Yevdokimova A, Lozhkina M, Yevdokimov V. Modern possibilities of optimizing the treatment of patients with hypertension and chronic heart failure in the application of torasemide. Russian Medical Journal. Cardiology. 2013;27:1388-1393. (Russian).
  27. Stebliuk V, Podolskiy O. Quality of life as a criterium of efficacy of pharmakologycal and physiotherapy complex in patients with arterial hypertension and chronic heart failure. Medical Hydrology and Rehabilitation. 2011;9(4):50-55. (Ukrainian).
  28. Stopinchuk O. Resistance to diuretic in chronic heart failure, ways of overcoming. Bukovinian Medical Herald Journal. 2013;17(4):191-196. (Ukrainian).
  29. Zhirov IV, Goryunova TV, Osmolovskaya YuF, Tereschenko SN. Prolonged-Release Torasemide in Patients with Chronic Heart Failure. Effective Pharmacotherapy. Cardiology and Angiology. 2014;3:18-23. (Russian).
  30. Chukaeva I, Orlova N, Soloveva M. Diuretics in patients with chronic heart failure: the quality of life and the effectiveness of therapy – is there room for compromise? Directory of the Polyclinic. 2014;2:29-32. (Russian).
  31. Chukaeva I, Orlova N, Soloveva M. Diuretic therapy in patients with chronic heart failure: an opportunity to improve the patient’s quality of life. Concilium medicum. 2014;16(5):51-55. (Russian).
  32. Yagenskiy A, Sіchkaruk І. Assessment of quality of life in modern medical practice. Internal medicine. 2007;3. Available from: http://www.mif-ua.com/archive/article/418. (Ukrainian).
  33. Yankovskaya V, Shiryaev O. Psychosomatic aspects of quality of life in patients with chronic heart failure. Young Scientist. 2014;17:219-222. (Russian).
  34. Nesbitt T, Doctorvaladan S, Southard JA, Singh S, Fekete A, Marie K et al. Correlates of quality of life in rural patients with heart failure. Circ Heart Failure. 2014;7(6):882-887. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000577
  35. Cosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Failure. 2002;4(4):507-513. https://doi.org/10.1016/S1388-9842(02)00122-8
  36. Garin O, Ferrer M, Pont A, Rué M, Kotzeva A, Wiklund I et al. Disease-specific health-related quality of life questionnaires for heart failure: a systematic review with meta-analyses. Qual Life Res. 2009;18(1):71-85. https://doi.org/10.1007/s11136-008-9416-4
  37. Macabasco-O’Connell A, Crawford MH, Stotts N, Stewart A, Froelicher ES. Gender and racial differences in psychosocial factors of low-income patients with heart failure. Heart Lung. 2010;39(1):2-11. https://doi.org/10.1016/j.hrtlng.2009.05.001
  38. Kraai IH, Vermeulen KM, Luttik ML, Hoekstra T, Jaarsma T, Hillege HL. Preferences of heart failure patients in daily clinical practice: quality of life or longevity? Eur J Heart Failure. 2013;15(10):1113-1121. https://doi.org/10.1093/eurjhf/hft071
  39. Hoekstra T, Jaarsma T, van Veldhuisen DJ, Hillege HL, Sanderman R, Lesman-Leegte I. Quality of life and survival in patients with heart failure. Eur J Heart Failure. 2013;15(1):94-102. https://doi.org/10.1093/eurjhf/hfs148
  40. Iqbal J, Francis L, Reid J, Murray S, Denvir M. Quality of life in patients with chronic heart failure and their carers a 3-year follow-up study assessing hospitalization and mortality. Eur J Heart Failure. 2010;12(9):1002-1008. https://doi.org/10.1093/eurjhf/hfq114
  41. Hoekstra T, Lesman-Leegte I, van Veldhuisen DJ, Sanderman R, Jaarsma T. Quality of life is impaired similarly in heart failure patients with preserved and reduced ejection fraction. Eur J Heart Failure. 2011;13(9):1013-1018. https://doi.org/10.1093/eurjhf/hfr072
  42. Lupón J, Gastelurrutia P, de Antonio M, González B, Cano L, Cabanes R et al. Quality of life monitoring in ambulatory heart failure patients: temporal changes and prognostic value. Eur J Heart Failure. 2013;15(1):103-109. https://doi.org/10.1093/eurjhf/hfs133
  43. Rector TS, Kubo SH, Cohn JN. Patients self-assessament of their congestive heart failure. Part 2. Content, realibility and validity of a new measure, the Minnesota Living with Heart failure Questionnaire. Heart Failure. 1987;3:198-207.
  44. Rector TS, Kubo SH, Cohn JN. Patients self-assessment of their congestive heart failure. Part 1. Patient perceived dysfunction and its poor correlation with maximal exercise tests. Heart Failure. 1987;3:192-196.
  45. Rector TS, Anand IS, Cohn JN. Relationships between clinical assessments and patients perceptions of the effects of heart failure on their quality of life. J Card Fail. 2006;12(2):87-92. https://doi.org/10.1016/j.cardfail.2005.10.002
  46. Stansfeld SA, Roberts R, Foot SP. Assessing the validity of the SF-36 General Health Survey. Qual Life Res. 1997;6(3):217-224. https://doi.org/10.1023/A:1026406620756
  47. Anguita M, Castro Beiras A, Cobo E, Coca A, De Teresa E, Díez J et al. Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study. Clin Ther. 2011;33(9):1204-1213. https://doi.org/10.1016/j.clinthera.2011.08.006
  48. Muller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV – efficacy and quality of life. Eur J Heart Failure. 2003;5(6):793-801. https://doi.org/10.1016/S1388-9842(03)00150-8
  49. Ware JE, Sherbourne CD. The MOS-SF36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-485. https://doi.org/10.1097/00005650-199206000-00002
  50. WHOQOL mesuaring quality of life. Geneva: World Health Organization, 1997. 15 р.